BANK OF NOVA SCOTIA (BNS) Form 424B3 — Aug 12, 2026
The Bank of Nova Scotia filed a preliminary pricing supplement (Amendment No. 1, dated August 11, 2026) under its Senior Note Program for auto-callable market-linked securities due August 24, 2029, linked to the lowest performing of AbbVie, Abbott Laboratories, Gilead Sciences and Eli Lilly common stock. The $1,000-face securities pay a monthly contingent coupon of at least 17.85% per annum only if the worst-performing underlying stock closes at or above 70% of its starting price, and are automatically called at par plus owed coupons if it closes at or above its starting price on any monthly calculation day from November 2026 to July 2029.
Key figures
- Maturity Date
- August 24, 2029
- Offering Price
- 1000
- Cusip
- 063941GV4
- Status
- Senior unsecured, unsubordinated obligations; not CDIC or FDIC insured; not bail-inable
- Issue date
- August 26, 2026
- Pricing date
- August 21, 2026
- Denominations
- $1,000 and any integral multiple of $1,000
- Max principal loss
- more than 40.00%, and possibly all, of face amount
- Automatic call window
- Monthly calculation days November 2026 to July 2029
- Coupon threshold price
- 70.00% of starting price
- Downside threshold price
- 60.00% of starting price
- Face amount per security
- $1,000.00
- Bank estimated value range
- $900.00 (90.000%) to $929.68 (92.968%) per security
- Min contingent coupon rate
- 17.85% per annum (paid monthly if conditions met)
- Agent discount per security
- $23.25 (2.325%)
- Proceeds to bank per security
- $976.75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.